Pulmonary Drug Delivery System Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Pulmonary Drug Delivery System Market Analysis
The pulmonary drug delivery systems market is expected to register a CAGR of 4% during the forecast period.
COVID-19 impacted the growth of the pulmonary drug delivery systems market. Patients suffering from respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) were at high risk of getting coronavirus infection. This has increased the demand for proper drug delivery systems for administering pulmonary drugs to patients. For instance, according to an article published in Pulmonary Medicine, in March 2022, it was observed that COPD patients have worse outcomes from the coronavirus infection. Also, due to biological factors, COPD patients are more likely to acquire viral infections and suffer from COVID-19's pathophysiological effects, such as micro thrombosis, intrapulmonary shunting, and subsequent bacterial infection. Thus, the increasing risk of developing COVID-19 infection among COPD patients increased the demand for inhalers and nebulizers, which impacted the demand for drug delivery systems during the pandemic. Hence, the COVID-19 pandemic had a favorable impact on the market initially; currently, as the pandemic has subsided, the market has lost some traction. However, it is expected to have stable growth during the forecast period.
Factors such as the increasing incidence of respiratory diseases, growing technological advancements, and rising preference for pulmonary drug delivery as an alternate route of drug delivery are boosting market growth.
The prevalence and incidence of respiratory diseases such as asthma, chronic obstructive pulmonary diseases, and others among the population are increasing rapidly, which is anticipated to increase the demand for pulmonary drug delivery systems, hence propelling market growth. For instance, according to an article published in ERS Journal, in August 2022, it was projected that about 645.6 million people (454.4 million men and 191.2 million women) are expected to have COPD by 2050, representing a 36% relative increase in global prevalence as compared to the previous year. Thus, the prevalence of COPD, a serious public health issue, is expected to rise, especially in emerging countries which is anticipated to increase the demand for different drug delivery systems such as nebulizers and inhalers. This is expected to fuel the market growth over the forecast period.
In addition, pulmonary drug delivery methods are preferred to conventional drug administration approaches due to the large surface area of the alveolar sacs, the high drug loading efficiency, and the high vascularization of the lung, which makes it an ideal site for drug absorption.
Furthermore, the rising company activities in developing novel drug delivery systems and increasing product launches are also expected to increase the growth of the pulmonary drug delivery systems market over the forecast period. For instance, in June 2021, Glenmark Pharma launched Tiotropium Bromide Dry Powder Inhaler, Tiogiva, used in the treatment of chronic obstructive pulmonary disease (COPD) in the United Kingdom. Also, in March 2021, PARI Pharma GmbH received the market authorization of the LAMIRA Nebulizer System for the delivery of Insmed's drug product ARIKAYCE (amikacin liposome inhalation suspension) in Japan.
Therefore, owing to factors such as the high burden of respiratory diseases among the population and increasing product launches, the studied market is expected to grow over the forecast period. However, the regulatory issues regarding the approval for drug delivery systems are likely to hamper the growth of the pulmonary drug delivery systems market over the forecast period.
Pulmonary Drug Delivery System Market Trends
This section covers the major market trends shaping the Pulmonary Drug Delivery System Market according to our research experts:
COPD Segment Expected to Register Significant Growth Over the Forecast Period
The chronic obstructive pulmonary diseases segment is expected to witness significant growth in the pulmonary drug delivery systems market over the forecast period. The factors attributing to the market growth are the increasing burden of COPD among the population and the growing demand for innovative drug delivery systems.
In addition, the rising geriatric population who are more prone to develop chronic obstructive pulmonary disease diseases due to the age-associated changes in the structure and function of the lung is also expected to increase the demand for the COPD drug segment over the forecast period. For instance, according to the 2022 statistics published by the United Nations Population Fund, about 59% of the total population living in Japan was aged between 15 and 64 in 2022. In addition, as per the same source, 29% of the population was aged 65 years and above in 2022.
The increasing prevalence and incidence of COPD is the key factor driving the demand for pulmonary drug delivery systems, hence propelling the segment's growth. According to a research study published in European Respiratory Journal in July 2021, it was found that the prevalence of chronic obstructive pulmonary disease (COPD) is anticipated to increase in Europe (including the Netherlands) due to rising risk factors like smoking and air pollution. Also, as per an article published in the European Respiratory Journal in November 2021, about 49,453,852 European are expected to suffer from COPD by 2050 as compared to 36,580,965 in 2020. This is expected to fuel the segment growth over the forecast period.
Moreover, the growing R&D activities and increasing product launches in the segment are expected to augment the growth of the chronic obstructive pulmonary diseases segment. For instance, in April 2022, GlaxoSmithKline Pharmaceuticals launched Trelegy Ellipta, a once-daily single-inhaler triple therapy (SITT) for treating patients suffering from chronic obstructive pulmonary diseases in India. Also, in October 2021, Glenmark launched a bioequivalent version of the Tiotropium Bromide dry powder inhaler (DPI) to treat chronic obstructive pulmonary disease (COPD) in Spain.
Therefore, owing to the factors such as the high burden of COPD and increasing product launches, the studied segment is expected to grow over the forecast period.
North America Holds Significant Share and Expected to do the Same in the Forecast Period
North America is expected to witness healthy growth in the pulmonary drug delivery systems over the forecast period owing to factors such as the increasing incidences of respiratory diseases such as asthma, allergic rhinitis, COPD, and others, the rising geriatric population, growing demand for diagnostic devices, increasing healthcare expenditure, and high disposable income.
The rising burden of respiratory diseases among the population is the key factor driving the demand for drug-delivery systems for treating various conditions, hence boosting market growth. For instance, according to an article published by MDPI in November 2021, it was observed that children with asthma in Mexico City are significantly correlated with respiratory problems and traffic-related air pollution, worsening the asthmatic condition in patients. Also, per the data published by IQAir, in August 2021, the US AQI value for Mexico City was 74, indicating "Moderate" levels of air pollution at the beginning of 2021. In addition, as per the same source, the components of "photochemical oxidizing smog" are discharged into the atmosphere in substantial amounts, including carbon monoxide, hydrocarbons, and nitrogen oxides from the exhaust of automobiles. Thus, the increasing discharge of pollutants in the air is expected to cause various respiratory allergies such as asthma, allergic rhinitis, and others among the population. This is anticipated to propel the demand for innovative and effective pulmonary drug delivery systems such as metered dose inhalers or nebulizers, hence bolstering market growth.
Furthermore, the rise in the number of initiatives undertaken by government and non-government organizations is increasing the overall revenue. For instance, CDC's National Asthma Control Program (NACP) provides funds for educating asthma-affected patients. Such initiatives are likely to increase awareness about asthma, which will increase the demand as well as the adoption of inhalers treating asthma, thereby propelling market growth.
Moreover, the presence of key market players in the country focusing on the development of effective pulmonary drugs as well as the rising adoption of various business strategies such as agreements, acquisitions, partnerships, and increasing product launches, are likely to boost the growth of the market. For instance, in March 2022, the US FDA approved the first generic of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of asthma in patients six years of age and older and the maintenance treatment of airflow obstruction and reducing exacerbations for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Therefore, the rising burden of respiratory diseases and increasing company activities and product launches in the country will significantly drive the market in the North American region during the study period.
Pulmonary Drug Delivery System Industry Overview
The pulmonary drug delivery systems market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Koninklijke Philips NV, GlaxoSmithKline PLC, 3M, Novartis AG, Boehringer Ingelheim International GmbH, AstraZeneca, Cipla Inc., Merck & Co., and GF Health Products Inc.
Pulmonary Drug Delivery System Market Leaders
Koninklijke Philips N.V
3M
Novartis AG
Boehringer Ingelheim International GmbH
GlaxoSmithKline plc.
*Disclaimer: Major Players sorted in no particular order
Pulmonary Drug Delivery System Market News
- Sept 2022: RIGImmune signed a deal to acquire Subintro, giving it access to novel topical delivery systems. The deal positions the biotech to advance the development of novel RNA therapies and vaccine adjuvants for local mucosal delivery.
- Aug 2022: Aptar Pharma acquired Orbital Dry Powder Inhaler (DPI) worldwide license. This acquisition will help Aptar Pharma meet the growing global demand for safe and convenient administration of high-dose treatments to the lungs.
Pulmonary Drug Delivery System Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Technological Advancements
4.2.2 Increasing Incidence of Respiratory Diseases and Growing Preference for Pulmonary Drug Delivery as an Alternate Route of Drug Delivery
4.3 Market Restraints
4.3.1 Strict Regulations for Drug Delivery Devices Approval
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1 By Product
5.1.1 Dry Powder Inhalers
5.1.2 Metered Dose Inhalers
5.1.3 Nebulizers
5.1.3.1 Jet Nebulizers
5.1.3.2 Soft Mist Nebulizers
5.1.3.3 Ultrasonic Nebulizers
5.2 By Application
5.2.1 Cystic Fibrosis
5.2.2 Asthma
5.2.3 Allergic Rhinitis
5.2.4 COPD
5.2.5 Other Applications
5.3 By End User
5.3.1 Hospitals
5.3.2 Diagnostic Centers
5.3.3 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Koninklijke Philips NV
6.1.2 GlaxoSmithKline PLC
6.1.3 3M
6.1.4 Novartis AG
6.1.5 Boehringer Ingelheim International GmbH
6.1.6 AstraZeneca
6.1.7 Cipla Inc.
6.1.8 Merck & Co.
6.1.9 GF Health Products Inc.
6.1.10 Aerogen
6.1.11 PARI GmbH
6.1.12 Gilbert Technologies
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Pulmonary Drug Delivery System Industry Segmentation
As per the scope of the report, pulmonary drug delivery systems deal with delivering the drug to the lung for the treatment of respiratory diseases. It is a non-invasive technique in which there is a large surface area of absorption and blood circulation, and the permeability rate is higher, which makes this technique an ideal method for the treatment of respiratory diseases. The Pulmonary Drug Delivery Systems Market is segmented by Product (Dry Powder Inhalers, Metered Dose Inhalers, and Nebulizers), Application (Cystic Fibrosis, Asthma, Allergic Rhinitis, COPD, and Other Applications), End User (Hospitals, Diagnostic Centers, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Product | |||||
| Dry Powder Inhalers | |||||
| Metered Dose Inhalers | |||||
|
| By Application | |
| Cystic Fibrosis | |
| Asthma | |
| Allergic Rhinitis | |
| COPD | |
| Other Applications |
| By End User | |
| Hospitals | |
| Diagnostic Centers | |
| Other End Users |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Pulmonary Drug Delivery System Market Research FAQs
What is the current Pulmonary Drug Delivery Systems Market size?
The Pulmonary Drug Delivery Systems Market is projected to register a CAGR of 4% during the forecast period (2024-2029)
Who are the key players in Pulmonary Drug Delivery Systems Market?
Koninklijke Philips N.V, 3M, Novartis AG, Boehringer Ingelheim International GmbH and GlaxoSmithKline plc. are the major companies operating in the Pulmonary Drug Delivery Systems Market.
Which is the fastest growing region in Pulmonary Drug Delivery Systems Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Pulmonary Drug Delivery Systems Market?
In 2024, the North America accounts for the largest market share in Pulmonary Drug Delivery Systems Market.
What years does this Pulmonary Drug Delivery Systems Market cover?
The report covers the Pulmonary Drug Delivery Systems Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Pulmonary Drug Delivery Systems Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Pulmonary Drug Delivery Systems Industry Report
Statistics for the 2024 Pulmonary Drug Delivery Systems market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Pulmonary Drug Delivery Systems analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
